Skip to content

Safety and efficacy of tDCS as an early augmentation (add on to medications) strategy in management of Obsessive Compulsive Disorder

Randomized, single blind, control trial of Transcranial Direct Current Stimulation in adults with Obsessive Compulsive Disorder as early augmentation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/049682
Enrollment
40
Registered
2023-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Active Transcranial Direct Current Stimulation: A total of 10 sessions (on a daily basis) of tDCS will be delivered over a period of two weeks following a uniform treatment protocol as

Sponsors

King Georges Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 18 years to 50 years 2. Informed consent to participate in the study 3. Symptomatic (Y-BOCS Score >16) patients of OCD diagnosed as per ICD-10 DCR. 4. Drug free for at least past 1 month

Exclusion criteria

Exclusion criteria: 1. Medical comorbidities that need immediate attention 2. Any contraindication to tDCS 3. Any other psychiatric comorbidity (except Depressive disorder, Anxiety disorder and tobacco use disorder) 4. Patient resistant to Fluoxetine (If previously treated) 5. Patient currently on any Psychotherapy.

Design outcomes

Primary

MeasureTime frame
Reduction of Y-BOCS scores (Obsessions, compulsions, total) at 2 weeks, 4 weeks and 6 weeksTimepoint: Assesment of Y-BOCS scores (Obsessions, compulsions, total) at baseline, 2 weeks, 4 weeks and 6 weeks

Secondary

MeasureTime frame
1. t-DCS side effect checklist 2. Change in subscales scores of Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A)Timepoint: 1) tDCS side effects assessed after 10 sessions of tdcs. 2) HAM-D and HAM-A scales at baseline, 2 weeks, 4 weeks and 6 weeks.

Countries

India

Contacts

Public ContactLokesh kumar

King Georges Medical University

drsujita@gmail.com9956273747

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026